Nanoparticles encapsulation
The small size along with the novel optical, electronic, and structural properties of nanoparticles that are not obtainable in discrete molecules or bulk solids, can be exploited to design customizable, targeted drug delivery systems capable of carrying different doses of drugs to the desired destin...
| Main Author: | |
|---|---|
| Format: | Conference or Workshop Item |
| Language: | English English |
| Published: |
2015
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/46354/ http://irep.iium.edu.my/46354/2/6th_Saudi_Conf_F%26N_programe2015.pdf http://irep.iium.edu.my/46354/3/Nanoparticles_Lecture_II.pdf |
| Summary: | The small size along with the novel optical, electronic, and structural properties of nanoparticles that are not obtainable in discrete molecules or bulk solids, can be exploited to design customizable, targeted drug delivery systems capable of carrying different doses of drugs to the desired destination. Certain drugs can be carried as prodrugs or inactive drugs, which on reaching the target, can be converted to become active. Alternatively, the drugs in the nanoparticle form can be conjugated with the targeting moiety, leading to the accumulation of conjugated nanoparticles in the target site. As a result the concentration of the drug at the target can reach 10 to 100 times more than dosage obtained by the direct administration of the drug.
Spurred by the launch of Abraxane as the first nanoparticle drug delivery system, researchers worldwide have put tremendous efforts into the development of nanoparticle-based drug carriers resulting in an exponential accumulation of novel nanoparticle systems and related research data. By the year 2014, there are 43 approved drug formulations which are marketed as nanopharmaceuticals. Many more nanotechnology-based systems are rapidly advancing towards preclinical and clinical trials for diagnosis and therapy. However, before propelling a new nanoparticle formulation from the bench to the bedside several challenges must first be addressed. Ideally, while in circulation, nanoparticle formulations should be stable and inert towards blood components. The carrier should protect the drug from systemic degradation while promoting controlled release properties at the target site. Additionally, the translation of promising nanodrug delivery systems can be accelerated with an improved understanding of various kinds of targeting moieties and biomarkers. The present lecture will focus on the recent advancements in nanoparticle-based drug delivery technology towards various target sites.
|
|---|